Study guide

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care

Key Takeaways Explain This Topic AI

Carriers of HLA-B*15:02 have a high risk of SJS/TEN with carbamazepine, oxcarbazepine and phenytoin or fosphenytoin, so another antiseizure drug is chosen when the result is known.

CYP2D6 ultrarapid metabolizers convert codeine and tramadol to active opioids too quickly; FDA contraindicates both drugs in children under 12 and after tonsillectomy or adenoidectomy in patients under 18.

Carbapenems lower valproate concentrations by 60 to 100% within about 24 hours, and raising the valproate dose does not overcome the interaction.

In CDC surveillance, anticoagulants, antibiotics, diabetes agents and opioids cause the largest share of ED visits for adverse drug events.

The Naranjo scale classifies causality as definite (9 or more), probable (5 to 8), possible (1 to 4) or doubtful (0 or less).

Last updated: October 2026

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care

Note

Exam scope: 2025 outline subtopics 2A4 (Pharmacokinetics, Pharmacodynamics and Pharmacogenomics) and 2C6 (Adverse Drug Events and Drug Interactions). Pharmacokinetic changes in critical illness are covered in Section 1.3, and dosing during renal replacement therapy in Section 11.4.

Pharmacogenomics in the ED

Genotype results are rarely available in the ED, but more patients now have prior results in the health record, and some gene-drug pairs are severe enough to change emergency choices. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes guidelines that translate a known genotype into a prescribing decision.

Gene Drugs Consequence and action

HLA-B*15:02 (most common in people of East and Southeast Asian ancestry) Carbamazepine, oxcarbazepine, phenytoin, fosphenytoin High risk of SJS/TEN. Avoid these drugs in carriers who have not taken them safely before; FDA labeling advises screening at-risk patients before starting carbamazepine

HLA-A*31:01 Carbamazepine DRESS and other hypersensitivity reactions

HLA-B*58:01 Allopurinol SJS/TEN and DRESS; ACR suggests testing patients of Southeast Asian or African American descent before starting it

HLA-B*57:01 Abacavir Hypersensitivity reaction; testing is required before use

CYP2D6 Codeine, tramadol ; also ondansetron and some antidepressants Ultrarapid metabolizers can develop fatal opioid toxicity; poor metabolizers get no analgesia

CYP2C19 Clopidogrel ; also voriconazole, some SSRIs and PPIs Poor or intermediate metabolizers activate less clopidogrel; use prasugrel or ticagrelor after ACS or PCI

CYP2C9 and VKORC1 Warfarin; phenytoin (CYP2C9) Lower doses are needed for sensitive genotypes

G6PD deficiency Rasburicase , pegloticase, primaquine, tafenoquine, dapsone, methylene blue Hemolysis, and methemoglobinemia with rasburicase; contraindicated or requires caution

RYR1 / CACNA1S Volatile anesthetics, succinylcholine Malignant hyperthermia susceptibility; avoid the triggers and keep dantrolene available

Butyrylcholinesterase (pseudocholinesterase) deficiency Succinylcholine, mivacurium Paralysis lasting hours; ask about family history of prolonged paralysis

DPYD Fluorouracil, capecitabine Severe or fatal toxicity. Uridine triacetate is the antidote for overdose or early-onset severe toxicity when started within 96 hours

TPMT, NUDT15 Azathioprine, mercaptopurine Severe myelosuppression

FDA action on codeine and tramadol (2017): both are contraindicated in children under 12 and after tonsillectomy or adenoidectomy in patients under 18 , and are not recommended during breastfeeding. Ultrarapid CYP2D6 metabolism caused deaths from respiratory depression.

  • Adverse Drug Events (ADEs)
  • Definitions

Adverse drug event: any injury resulting from medication use, whether or not an error occurred.

Adverse drug reaction: a harmful, unintended response at normal doses.

Medication error: a preventable event in prescribing, transcribing, dispensing, administering or monitoring that may or may not cause harm (Section 14.1).

Type Description Examples

Type A (augmented) Predictable from the drug's pharmacology and dose-related; most ADEs Bleeding with anticoagulants, hypoglycemia with insulin, respiratory depression with opioids

Type B (bizarre) Unpredictable, immunologic or idiosyncratic Anaphylaxis, SJS/TEN, DRESS

CDC's national surveillance of ED visits finds that anticoagulants, antibiotics, diabetes agents and opioids account for the largest share of ED visits for adverse drug events. In older adults, anticoagulants and diabetes agents lead the list.

Assessing Causality: The Naranjo Scale

The Naranjo algorithm scores 10 questions about timing, dechallenge, rechallenge, alternative causes, drug levels and previous reports.

  • Total score Category
  • 9 or more Definite
  • 5 to 8 Probable
  • 1 to 4 Possible
  • 0 or less Doubtful

Report serious reactions to FDA MedWatch and vaccine reactions to VAERS (Section 14.1).

Severe Cutaneous Adverse Reactions

  • Feature SJS/TEN DRESS
  • Usual onset after starting the drug 4 to 28 days 2 to 8 weeks

Skin Painful dusky lesions, blisters, skin detachment (under 10% of the body surface in SJS, over 30% in TEN), mucosal erosions Widespread rash, facial swelling

Systemic Fever, mucosal involvement in at least two sites Fever, eosinophilia , atypical lymphocytes, organ involvement (liver most often, also kidney, lung, heart)

Common culprits Allopurinol, carbamazepine, lamotrigine (especially with fast titration or valproate), phenytoin, sulfonamides, oxicam NSAIDs, nevirapine Antiseizure drugs, allopurinol, vancomycin , minocycline, sulfonamides

Management Stop the drug immediately , burn or ICU care, eye care; prognosis by SCORTEN Stop the drug; systemic corticosteroids for organ involvement

Record the causative drug as an allergy, not just an intolerance, and tell the patient never to take it again.

Drug-Induced QT Prolongation

Risk rises with female sex, older age, hypokalemia, hypomagnesemia, bradycardia, structural heart disease, kidney or liver impairment and combinations of QT-prolonging drugs . Common ED examples are ondansetron, droperidol, haloperidol, methadone, azithromycin, fluoroquinolones, citalopram and quetiapine. Correct potassium and magnesium, check a baseline ECG when combining drugs in at-risk patients, and give IV magnesium for torsades de pointes (Section 2.2).

High-Risk Drug Interactions the ED Pharmacist Must Catch

Combination Mechanism and result Action

Carbapenem + valproate Valproate concentrations fall 60 to 100% within about 24 hours, and raising the dose does not overcome it; breakthrough seizures Choose a non-carbapenem antibiotic or switch to another antiseizure drug

Linezolid or methylene blue + SSRIs, SNRIs, MAO inhibitors MAO inhibition causes serotonin syndrome Avoid, or monitor closely when there is no alternative (Section 17.7)

Trimethoprim-sulfamethoxazole + warfarin CYP2C9 inhibition raises the INR Choose another antibiotic or monitor the INR

Trimethoprim-sulfamethoxazole + ACE inhibitor, ARB or spironolactone Trimethoprim blocks potassium excretion, causing hyperkalemia Check potassium; avoid in older adults with CKD

Metronidazole or fluconazole + warfarin CYP2C9 inhibition raises the INR Adjust warfarin and monitor

Clarithromycin or erythromycin + simvastatin, colchicine, calcium channel blockers or DOACs CYP3A4 and P-gp inhibition: rhabdomyolysis, fatal colchicine toxicity, hypotension, bleeding Use azithromycin or doxycycline; hold the statin

Nirmatrelvir-ritonavir + many drugs Strong CYP3A4 inhibition (for example amiodarone, some statins, tacrolimus, some DOACs) Screen every prescription for interactions

Rifampin + DOACs, warfarin, tacrolimus, hormonal contraceptives Strong enzyme induction causes loss of effect Avoid the combination or monitor closely

PDE5 inhibitors + nitrates Profound hypotension No nitrate within 24 hours of sildenafil or 48 hours of tadalafil

Opioids + benzodiazepines Additive respiratory depression (FDA boxed warning) Avoid co-prescribing; prescribe naloxone

Lithium + NSAIDs, ACE inhibitors, ARBs or thiazides Lower lithium clearance and toxicity Avoid or monitor levels (Section 17.7)

Allopurinol + azathioprine or mercaptopurine Xanthine oxidase inhibition causes myelosuppression Reduce the thiopurine dose sharply or avoid

Clopidogrel + omeprazole or esomeprazole CYP2C19 inhibition reduces clopidogrel activation Use pantoprazole if a PPI is needed

Ceftriaxone + calcium-containing IV solutions in neonates Fatal precipitation Never give together in neonates up to 28 days old